Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):29. doi: 10.1167/iovs.64.7.29.
To summarize an invited lecture topic from the proceedings of the International Society of Ocular Oncology meeting in Leiden in 2022. Mechanism of action, indications, and the authors' clinical experience with immune checkpoint inhibitors in patients with locally advanced ocular adnexal squamous cell carcinoma are summarized. Several cases of locally advanced conjunctival, eyelid, and lacrimal sac/duct squamous cell carcinoma that were successfully treated with immune checkpoint inhibitors (PD-1 directed) are shared. Immune checkpoint inhibitors are effective at reducing tumor size and enabling eye-preserving surgery in patients with locally advanced ocular adnexal squamous cell carcinoma with orbital invasion. They present a new strategy for the treatment of locally advanced squamous cell carcinoma of the ocular adnexa and orbit.
总结 2022 年在莱顿举行的国际眼肿瘤学会会议的一篇演讲主题。总结免疫检查点抑制剂在局部晚期眼附属器鳞状细胞癌患者中的作用机制、适应证和作者的临床经验。分享了几例局部晚期结膜、眼睑和泪囊/管鳞状细胞癌，这些患者成功地接受了免疫检查点抑制剂（PD-1 靶向）治疗。免疫检查点抑制剂可有效缩小肿瘤大小，使伴有眼眶侵犯的局部晚期眼附属器鳞状细胞癌患者能够进行保眼手术。它们为局部晚期眼附属器和眼眶鳞状细胞癌的治疗提供了一种新策略。
